author-photo

Ofri Mosenzon

Brigham and Women's Hospital

8

Papers

41

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL

2020 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (3)
Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial

2019 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (35)
Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial

2019 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53

2018 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK

2017 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL

2014 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)